IP Library › Granted Patent US 12,485,120
Granted Patent B2
US 12,485,120 · App. 19/079,727 · Granted Dec 2, 2025

Methods of treating disorders using CSF1R inhibitors

Inventors: Daniel L. Flynn (Waltham, MA); Bryan D. Smith (Waltham, MA); Rodrigo Ruiz Soto (Waltham, MA); Keisuke Kuida (Waltham, MA)
Assignee: Deciphera Pharmaceuticals, LLC
A61K31/513A61K9/0053A61K45/06A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,485,120
App. No.
19/079,727
Filed
Mar 14, 2025
Granted
Dec 2, 2025
Kind
B2
Art Unit
1629
USPC
514/272
Abstract

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

Claims (23)

1 . A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient: a pharmaceutical composition comprising a therapeutically effective amount of a compound represented by:

wherein after 1 month or more of administration, the patient has: (i) an improved tumor response as measured by CT, MRI and/or RECIST; and/or (ii) an improved range of motion; and/or (iii) reduced macrophage infiltration in the affected joint and/or circulating chemokine/cytokines associated with inflammation as compared to the amounts before administration.

2 . The method of claim 1 , wherein the tumor is benign.

3 . The method of claim 1 , wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor.

4 . The method of claim 1 , wherein the therapeutically effective amount is about 2 mg to about 60 mg of the compound, and the composition is administered twice weekly.

5 . The method of claim 1 , wherein the therapeutically effective amount is about 5 mg to about 30 mg of the compound and the composition is administered twice weekly.

6 . The method of claim 1 , comprising administering to the patient the composition twice weekly for about 3 months.

7 . The method of claim 1 , comprising administering to the patient the composition twice weekly for about 6 months.

8 . The method of claim 1 , comprising administering to the patient the composition twice weekly for about 1 year.

9 . The method of claim 1 , comprising administering to the patient the composition twice weekly for about 2 years.

10 . A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising 30 mg of a compound represented by:

twice weekly, wherein after 1 month or more of administration, the patient has:

(i) an improved tumor response as measured by CT, MRI and/or RECIST; and/or

(ii) an improved range of motion; and/or (iii) reduced macrophage infiltration in the affected joint and/or circulating chemokine/cytokines associated with inflammation as compared to the amounts before administration.

11 . The method of claim 10 , wherein the tumor is benign.

12 . The method of claim 10 , wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor.

13 . The method of claim 10 , comprising administering to the patient the composition twice weekly for about 3 months.

14 . The method of claim 10 , comprising administering to the patient the composition twice weekly for about 6 months.

15 . The method of claim 10 , comprising administering to the patient the composition twice weekly for about 1 year.

16 . The method of claim 10 , comprising administering to the patient the composition twice weekly for about 2 years.

17 . A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising 30 mg of a compound represented by:

18 . The method of claim 17 , wherein the tumor is benign.

19 . The method of claim 17 , wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2025
From: FLYNN, DANIEL L.; SMITH, BRYAN D.; KUIDA, KEISUKE; SOTO, RODRIGO RUIZ
To: DECIPHERA PHARMACEUTICALS, LLC
Reel/Frame 072596/0048 →
Continuity (7)
Continuation 18140942 · Apr 28, 2023
Continuation 17358137 · Jun 25, 2021
Continuation 16725282 · Dec 23, 2019
Provisional Application 62933830 · Nov 11, 2019
Provisional Application 62926341 · Oct 25, 2019
Provisional Application 62786105 · Dec 28, 2018
Related Publication 20250205237A1 · Jun 26, 2025
References Cited (119)
US 7144911B2 · Flynn et al. · 2006 [cited by applicant]
US 7202257B2 · Flynn et al. · 2007 [cited by applicant]
US 7279576B2 · Flynn et al. · 2007 [cited by applicant]
US 7342037B2 · Flynn et al. · 2008 [cited by applicant]
US 7531566B2 · Flynn et al. · 2009 [cited by applicant]
US 7666895B2 · Flynn et al. · 2010 [cited by applicant]
US 7737283B2 · Flynn et al. · 2010 [cited by applicant]
US 7790756B2 · Flynn et al. · 2010 [cited by applicant]
US 7897762B2 · Flynn et al. · 2011 [cited by applicant]
US 8143293B2 · Flynn et al. · 2012 [cited by applicant]
US 8163756B2 · Flynn et al. · 2012 [cited by applicant]
US 8188113B2 · Flynn et al. · 2012 [cited by applicant]
US 8278331B2 · Flynn et al. · 2012 [cited by applicant]
US 8461179B1 · Flynn et al. · 2013 [cited by applicant]
US 8486951B2 · Flynn et al. · 2013 [cited by applicant]
US 8569319B2 · Flynn et al. · 2013 [cited by applicant]
US 8586565B2 · Flynn et al. · 2013 [cited by applicant]
US 8637672B2 · Flynn et al. · 2014 [cited by applicant]
US 8741911B2 · Allgeier et al. · 2014 [cited by applicant]
US 8921565B2 · Flynn et al. · 2014 [cited by applicant]
US 8940756B2 · Flynn et al. · 2015 [cited by applicant]
US 9012635B2 · Flynn et al. · 2015 [cited by applicant]
US 9133183B2 · Flynn et al. · 2015 [cited by applicant]
US 9181223B2 · Kaufman et al. · 2015 [cited by applicant]
US 9187474B2 · Flynn et al. · 2015 [cited by applicant]
US 9193719B2 · Flynn et al. · 2015 [cited by applicant]
US 9309224B2 · Flynn et al. · 2016 [cited by applicant]
US 9334267B2 · Flynn et al. · 2016 [cited by applicant]
US 9382228B2 · Flynn et al. · 2016 [cited by applicant]
US 9387202B2 · Flynn et al. · 2016 [cited by applicant]
US 9457019B2 · Flynn et al. · 2016 [cited by applicant]
US 11103507B2 · Flynn · 2021 [cited by examiner]
US 11679110B2 · Flynn · 2023 [cited by examiner]
US 20080214544A1 · Bellon et al. · 2008 [cited by applicant]
US 20080255155A1 · Raeppel et al. · 2008 [cited by applicant]
US 20100120806A1 · Flynn et al. · 2010 [cited by applicant]
US 20100166699A1 · Thompson et al. · 2010 [cited by applicant]
US 20110053906A1 · Huck et al. · 2011 [cited by applicant]
US 20140145025A1 · Fang et al. · 2014 [cited by applicant]
US 20150073129A1 · Herting et al. · 2015 [cited by applicant]
US 20190091217A1 · Flynn et al. · 2019 [cited by applicant]
US 20200129489A1 · Flynn et al. · 2020 [cited by applicant]
US 20200352920A1 · Flynn et al. · 2020 [cited by applicant]
US 20200354346A1 · Flynn et al. · 2020 [cited by applicant]
US 20200354352A1 · Flynn et al. · 2020 [cited by applicant]
US 20210015801A1 · Flynn et al. · 2021 [cited by applicant]
CN 105120864A · 2015 [cited by applicant]
CN 105473617A · 2016 [cited by applicant]
CN 113880812A · 2022 [cited by applicant]
CN 116283919A · 2023 [cited by applicant]
EP 3632907A1 · 2020 [cited by applicant]
EP 3682881A1 · 2020 [cited by applicant]
JP 6364472B2 · 2018 [cited by applicant]
RU 2330024C2 · 2008 [cited by applicant]
WO WO2003000660A1 · 2003 [cited by applicant]
WO WO2008079291A2 · 2008 [cited by applicant]
WO WO2010051373A1 · 2010 [cited by applicant]
WO WO2014145025A2 · 2014 [cited by applicant]
WO WO2014145015A2 · 2014 [cited by applicant]
WO WO2014145028A2 · 2014 [cited by applicant]
WO WO2022247786A1 · 2022 [cited by applicant]
“Deciphera Pharmaceuticals Announces Positive, Preliminary, Top-Line Clinical Data for the Ongoing Phase 1 Clincial Study with DCC-3014 and an Update on Future Development Plans,” 2019, 1-3. [cited by applicant]
“History of Changes for Study: NCT03069469 Study of DCC-3014 in Patients with Advanced Malignancies,” ClinicalTrials.gov Archive, 2018, 1-5. [cited by applicant]
Al-Muhsen et al., “The Expression of Stem Cell Factor and c-Kit Receptor in Human Asthmatic Airways,” Clinical and Experimental Allergy, 2004, 34: 911-917. [cited by applicant]
Attoub et al., “The C-Kit Tyrosine Kinase Inhibitor STI571 for Colorectal Cancer Therapy,” Cancer Research, 2002, 62: 4879-4883. [cited by applicant]
Blay, JY et al., “P63: Patient-Reported Outcomes Following Treatment with Vimseltinib for Tenosynovial Giant Cell Tumour in a Phase 2 Expansion Study”, Value in Health, Elsevier, Amsterdam, NL, vol. 25, No. 12 (Dec. 1, … [cited by applicant]
Boisson et al., “c-Kit and c-kit mutations in mastocytosis and other hematological diseases,” Journal of Leukocyte Biology, 2000, 67(2):135-148. [cited by applicant]
Brinkmann et al., “Fingolimod (FTY720): Discovery and Development of an Oral Drug to Treat Multiple Sclerosis,” Nature Reviews | Drug Discovery, 2010, 9: 883-897. [cited by applicant]
Brunton et al., “Chemotherapy of Neoplastic Diseases,” in, Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 2008, 11th ed.: 853-908. [cited by applicant]
Burns et al., “C-FMS Inhibitors: A Patent Review,” Expert Opinion on Therapeutic Patents, 2011, 147-165. [cited by applicant]
Caira, M. A., Crystalline Polymorphism of Organic Compounds, Design of Organic Solids, Topics in Current Chemistry, 198, 163-208, (1998). [cited by applicant]
Caldwell, T. M. et al., “Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT),” Biorg. Med. Che… [cited by applicant]
Carvajal et al., “KIT as a Therapeutic Target in Metastatic Melanoma,” Journal of the American Medical Association, 2011, 305(22): 2327-2334. [cited by applicant]
Dewar et al., “Inhibition of c-fms by Imatinib: expanding the spectrum of treatment,” Cell Cycle, 2005, 4(7):851-853. [cited by applicant]
Dewar et al., “Macrophage Colony-Stimulating Factor Receptor C-Fms is a Novel Target of Imatinib,” Blood, 2005, 105(8): 3127-3132. [cited by applicant]
Di Lorenzo et al., “Expression of Proto-Oncogene C-Kit in High Risk Prostate Cancer,” European Journal of Surgical Oncology, 2004, 30: 987-992. [cited by applicant]
Dorwald, “Side Reactions in Organic Synthesis,” Wiley: VCH Weinhem Preface, 2005, 1-15 & 8: 279-308. [cited by applicant]
El Agamy et al., “Targeting c-Kit in the Therapy of Mast Cell Disorders: Current Update,” European Journal of Pharmacology, 2012, 690: 1-3. [cited by applicant]
Fang, Z. et al., Conformational restriction: an effective tactic in ‘follow-on’-based drug discovery, Future Med. Chem., 6(8): 885-901, (2014). [cited by applicant]
Fine et al., “Neoplasms of the Central Nervous System,” Cancer Principles & Practice of Oncology, 2005, 1834-1887. [cited by applicant]
Fogarty et al., “Development of Protein Kinase Activators: AMPK as a Target in Metabolic Disorders and Cancer,” Biochimica et Biophysica Acta, 2010, 1804: 581-591. [cited by applicant]
Gelderblom, H. et al., “475P: Safety and Efficacy of Vimseltinib in Tenosynovial Giant Cell Tumour (TGCT)): Long-term Phase I Update”, Annals of Oncology, vol. 33, (Sep. 1, 2022), p. S757, XP093241096. [cited by applicant]
Gelderblom, H. et al., “Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial”, The Lancet, vol. 403, No. 10445, (Jun. 3, 2024… [cited by applicant]
Girouard et al., “Neurovascular Coupling in the Normal Brain and in Hypertension, Stroke, and Alzheimer Disease,” J. Appl Physiol., 2006, 100: 328-335. [cited by applicant]
Gupta et al., “IL-3 Inhibits Human Osteoclastogenesis and Bone Resorption through Downregulation of c-Fms and Diverts the Cells to Dendritic Cell Lineage,” The Journal of Immunology, 2010, 2261-2272. [cited by applicant]
Heinrich et al., “Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor,” Blood, 2000, 96(3):925-932. [cited by applicant]
Henriksen et al., “Assessment of Osteoclast Number and Function: Application in the Development of New and Improved Treatment Modalities For Bone Diseases,” Osteoporosis International, 2006, 18: 681-685. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2014/029661 mailed Jun. 11, 2014. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2014/029664 mailed Jun. 11, 2014. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2019/068311 mailed Jul. 2, 2020. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2024/053261 mailed Feb. 6, 2025. [cited by applicant]
Judge et al., “Potassium Channel Blockers in Multiple Sclerosis: Neuronal Kv Channels and Effects of Symptomatic Treatment,” Pharmacology & Therapeutics, 2006, 224-259. [cited by applicant]
Kumari, A. et al., 3D-QSAR analysis of anilinoquinoline inhibitors of colony stimulating factor-1 kinase(cFMS): implementation of field-based molecular alignment, Med. Chem. Res., 22, 5167-5183 (2013). [cited by applicant]
Kung et al., “Structure Activity Relationships of Quinoline-Containing c-Met Inhibitors,” European Journal of Medicinal Chemistry 43, 2008, 1321-1329. [cited by applicant]
Kuster et al., “Kinase Inhibitors Methods and Protocols,” Methods in Molecular Biology, 2012, 1-46. [cited by applicant]
Lewitt, “Levodopa for the Treatment of Parkinson's Disease,” New England Journal of Medicine, 2008, 359: 2468-2476. [cited by applicant]
Luo et al., “Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction,” Cell, 2009, 36: 823-837. [cited by applicant]
Minkin, “Bone Acid Phosphatase: Tartrate-Resistant Acid Phosphatase as a Marker of Osteoclast Function,” Calcified Tissue International, 1982, 34: 285-290. [cited by applicant]
Mitchell et al., “Amyotrophic Lateral Sclerosis,” The Lancet, 2007, 369: 2031-2041. [cited by applicant]
National Cancer Institute (http://www.cancer.gov) 2014. [cited by applicant]
O'Brien et al., “Vascular Cognitive Impairment,” The Lancet Neurology, 2003, 2: 89-98. [cited by applicant]
Ohno et al., “A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model,” Mol Cancer Ther., 2006, 5(11):2634-2643. [cited by applicant]
PCT/US2024/058988 International Search Report and Written Opinion mailed Mar. 24, 2025, 12 pages. [cited by applicant]
PCT/US2024/060067 International Search Report and Written Opinion mailed Apr. 10, 2025, 48 pages. [cited by applicant]
Pyonteck et al., “CSF-1R inhibition alters macrophage polarization and blocks glioma progression,” Nature Medicine, 2013, 19(10):1264-1274. [cited by applicant]
Reber et al., “Stem Cell Factor and its Receptor c-Kit as Targets for Inflammatory Diseases,” European Journal of Pharmacology, 2006, 533: 327-340. [cited by applicant]
Roberts et al., “Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitor, CP-673, 451,” Cancer Research, 2005, 957-966. [cited by applicant]
Rubin et al., “KIT activation is a ubiquitous feature of gastrointestinal stromal tumors,” Cancer Research, 2001, 61(22):8118-8121. [cited by applicant]
Shah et al., “Current Approaches in the Treatment of Alzheimer's Disease,” Biomedicine & Pharmacotherapy, 2008, 62: 199-207. [cited by applicant]
Silverman, R. B. et al., The Organic Chemistry of Drug Design and Drug Action, 3rd Ed, Chapter 2, 19-122, Elsevier, (2014). [cited by applicant]
Smith, B. D. et al., “Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages”, Molecular Cancer Therapeutics, vol. 20, No. 11, (Aug. 25, 2021), pp. 2098-2109, XP09… [cited by applicant]
Tap et al., “Pexidartinib Versus Placebo for Advanced Tenosynovial Giant Cell Tumour (ENLIVEN): a Randomised Phase 3 Trial,” Lancet, 2019, 394: 478-487. [cited by applicant]
Tap et al., “Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor,” New England Journal of Medicine, 2015, 373(5):428-437. [cited by applicant]
Tap, W. D. et al., “Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial”, Journal of Clinical Oncology, vol. 42, No. 16_su… [cited by applicant]
Tap, W. D. et al., “Motion: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumour”, Journal of Clinical Oncology, vol. 40, No. 16_sup… [cited by applicant]
Wen et al., “Osteosarcoma Cell-Intrinsic Colony Stimulating Factor-1 Receptor Functions to Promote Tumor Cell Metastasis Through JAG1 Signaling,” American Journal of Cancer Research, 2017, 7(4): 801-815. [cited by applicant]
Yasuda et al., “The Stem Cell Factor/C-Kit Receptor Pathway Enhance Proliferation and Invasion of Pancreatic Cancer Cells,” Molecular Cancer, 2006, 5(46): 1-10. [cited by applicant]
PCT/US2024/058998 International Search Report and Written Opinion mailed Jun. 2, 2025, 11 pages. [cited by applicant]
Khadka, P. et al., Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability, Asian Journal of Pharmaceutical Sciences, 9(6): 304-316 (2014). [cited by applicant]
Cited By (1)
US 12,708,617